AMA submission to the PBS Life Saving Drugs Program Review

The AMA's submission ​to the Department of Health's review of the Life Saving Drugs Program recommended future Government funding of medicines for rare diseases should be made under a framework that supports consistently applied, quantifiable and evidence-based decisions to initiate, continue and/or discontinue therapies and subsidies.